Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Colorectal Neoplasms

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 55 articles: HTML format

Single Articles

July 2025
1. SEO JW, Kim JY, Ha YJ, Tak KH, et al
   Prognostic and therapeutic value of a 23-gene risk score tailored to the molecular characteristics of mucinous colorectal cancer.
   Br J Cancer. 2025 Jul 2. doi: 10.1038/s41416-025-03104.
   PubMed     Abstract available
   
   
   June 2025
2. MESA-EGUIAGARAY I, Iakovliev A, Li X, Timofeeva M, et al
   Association between methylation quantitative trait loci and colorectal cancer risk, survival and cancer recurrence.
   Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03064.
   PubMed     Abstract available
   
   
   
3. ZHONG W, Zhang Y, Wang W, Shao Z, et al
   TRIM26 deficiency potentially suppresses colorectal cancer liver metastasis through NF-kappaB-mediated M1-like tumor-associated macrophage polarization.
   Br J Cancer. 2025 Jun 9. doi: 10.1038/s41416-025-03072.
   PubMed     Abstract available
   
   
   
4. RUBIO-CUESTA B, Carretero-Puche C, Llamas P, Sarmentero J, et al
   Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer.
   Br J Cancer. 2025 Jun 6. doi: 10.1038/s41416-025-03058.
   PubMed     Abstract available
   
   
   
5. ANDEL D, Nouwens AJ, Klaassen S, Laoukili J, et al
   Rational design of alternative treatment options for radioresistant rectal cancer using patient-derived organoids.
   Br J Cancer. 2025;132:973-981.
   PubMed     Abstract available
   
   
   April 2025
6. YUAN F, Jia G, Wen W, Xu S, et al
   Blood metabolic biomarkers and colorectal cancer risk: results from large prospective cohort and Mendelian randomisation analyses.
   Br J Cancer. 2025 Apr 30. doi: 10.1038/s41416-025-02997.
   PubMed     Abstract available
   
   
   
7. REITSAM NG, Markl B
   Stroma AReactive Invasion Front Areas (SARIFA) and the tumour immune microenvironment in colorectal cancer.
   Br J Cancer. 2025 Apr 26. doi: 10.1038/s41416-025-03034.
   PubMed    
   
   
   
8. LEE HJ, Park SW, Lee JH, Chang SY, et al
   Correction: Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes.
   Br J Cancer. 2025 Apr 11. doi: 10.1038/s41416-025-02988.
   PubMed    
   
   
   
9. HASJIM BJ, Ostowari A, Gandawidjaja M, Mohammadi MD, et al
   De novo colorectal cancer after kidney transplantation: a systematic review and meta-analysis.
   Br J Cancer. 2025 Apr 5. doi: 10.1038/s41416-025-02994.
   PubMed     Abstract available
   
   
   
10. ELOMAA H, Tarkiainen V, Aijala VK, Sirnio P, et al
    Associations of mucinous differentiation and mucin expression with immune cell infiltration and prognosis in colorectal adenocarcinoma.
    Br J Cancer. 2025;132:660-669.
    PubMed     Abstract available
    
    
    March 2025
11. GRANCHER A, Beaussire-Trouvay L, Vernon V, Dutherage M, et al
    ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer.
    Br J Cancer. 2025 Mar 15. doi: 10.1038/s41416-025-02971.
    PubMed     Abstract available
    
    
    
12. TANG F, Zhu Y, Shen J, Yuan B, et al
    CD44(+) cells enhance pro-tumor stroma in the spatial landscape of colorectal cancer leading edge.
    Br J Cancer. 2025 Mar 12. doi: 10.1038/s41416-025-02968.
    PubMed     Abstract available
    
    
    
13. TAPIAINEN VV, Sirnio P, Elomaa H, Karjalainen H, et al
    Stroma AReactive Invasion Front Areas (SARIFA), tumour immune microenvironment, and survival in colorectal cancer.
    Br J Cancer. 2025 Mar 7. doi: 10.1038/s41416-025-02972.
    PubMed     Abstract available
    
    
    
14. LEE HJ, Park SW, Lee JH, Chang SY, et al
    Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes.
    Br J Cancer. 2025 Mar 3. doi: 10.1038/s41416-025-02964.
    PubMed     Abstract available
    
    
    February 2025
15. ZHANG Y, Wu D, Zhang Z, Ma J, et al
    Correction: Impact of lymph node metastasis on immune microenvironment and prognosis in colorectal cancer liver metastasis: insights from multiomics profiling.
    Br J Cancer. 2025 Feb 17. doi: 10.1038/s41416-025-02941.
    PubMed    
    
    
    
16. BUNDRED J, Lal N, Chan DKH, Buczacki SJA, et al
    Lymph node yield as a surrogate marker for tumour biology and prognosis in colon cancer.
    Br J Cancer. 2025 Feb 14. doi: 10.1038/s41416-025-02949.
    PubMed     Abstract available
    
    
    
17. KATO Y, Seishima R, Hattori K, Kato H, et al
    Significance of homologous recombinant deficiency as a biomarker for drug sensitivity in colorectal cancer.
    Br J Cancer. 2025 Feb 11. doi: 10.1038/s41416-025-02950.
    PubMed     Abstract available
    
    
    January 2025
18. ZHANG Y, Wu D, Zhang Z, Ma J, et al
    Impact of lymph node metastasis on immune microenvironment and prognosis in colorectal cancer liver metastasis: insights from multiomics profiling.
    Br J Cancer. 2025 Jan 3. doi: 10.1038/s41416-024-02921.
    PubMed     Abstract available
    
    
    December 2024
19. LIU C, Reger M, Fan H, Wang J, et al
    Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
    PubMed     Abstract available
    
    
    November 2024
20. PRETTA A, Ziranu P, Perissinotto E, Ghelardi F, et al
    Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon.
    Br J Cancer. 2024 Nov 27. doi: 10.1038/s41416-024-02902.
    PubMed     Abstract available
    
    
    
21. CHAN WC, Liu L, Bouras E, Zuber V, et al
    Associations of blood lipids and LDL cholesterol lowering drug-targets with colorectal cancer risk: a Mendelian randomisation study.
    Br J Cancer. 2024 Nov 23. doi: 10.1038/s41416-024-02900.
    PubMed     Abstract available
    
    
    
22. POGHOSYAN S, Frenkel N, van den Bent L, Raats D, et al
    VEGF-C propagates 'onward' colorectal cancer metastasis from liver to lung.
    Br J Cancer. 2024 Nov 9. doi: 10.1038/s41416-024-02892.
    PubMed     Abstract available
    
    
    
23. CAMPOS GUDINO R, Neudorf NM, Andromidas D, Lichtensztejn Z, et al
    Loss of EMI1 compromises chromosome stability and is associated with cellular transformation in colonic epithelial cell contexts.
    Br J Cancer. 2024;131:1516-1528.
    PubMed     Abstract available
    
    
    October 2024
24. LI B, Yang W, Liu N, Bi D, et al
    Phase II Study of Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab as a Later-line Therapy for Patients with Metastatic Colorectal Cancer (mCRC): a prospective single-center explorative study.
    Br J Cancer. 2024 Oct 24. doi: 10.1038/s41416-024-02885.
    PubMed     Abstract available
    
    
    
25. OGAARD N, Jensen SO, Orntoft MW, Demuth C, et al
    Circulating tumour DNA and risk of recurrence in patients with asymptomatic versus symptomatic colorectal cancer.
    Br J Cancer. 2024 Oct 10. doi: 10.1038/s41416-024-02867.
    PubMed     Abstract available
    
    
    
26. NOH H, Lee J, Seyed Khoei N, Peruchet-Noray L, et al
    Serum bilirubin levels and risk of colorectal cancer in Korean adults: results from the Korean Genome and Epidemiology Study-Health Examinee (KoGES-HEXA) Cohort Study.
    Br J Cancer. 2024 Oct 8. doi: 10.1038/s41416-024-02847.
    PubMed     Abstract available
    
    
    
27. SEKHAR H, Kochhar R, Carrington B, Kaye T, et al
    Pre-treatment magnetic resonance imaging in anal cancer: large-scale evaluation of mrT, mrN and novel staging parameters.
    Br J Cancer. 2024;131:1137-1146.
    PubMed     Abstract available
    
    
    September 2024
28. AMODIO V, Vitiello PP, Bardelli A, Germano G, et al
    DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors.
    Br J Cancer. 2024 Sep 13. doi: 10.1038/s41416-024-02848.
    PubMed     Abstract available
    
    
    
29. BOLAND PM, Mukherjee S, Imanirad I, Vijayvergia N, et al
    TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial.
    Br J Cancer. 2024 Sep 7. doi: 10.1038/s41416-024-02845.
    PubMed     Abstract available
    
    
    
30. CHOWDHURY S, Xiu J, Ribeiro JR, Nicolaides T, et al
    Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors.
    Br J Cancer. 2024 Sep 4. doi: 10.1038/s41416-024-02826.
    PubMed     Abstract available
    
    
    August 2024
31. GWENZI T, Schrotz-King P, Anker SC, Schottker B, et al
    Prognostic value of post-operative iron biomarkers in colorectal cancer: population-based patient cohort.
    Br J Cancer. 2024 Aug 27. doi: 10.1038/s41416-024-02814.
    PubMed     Abstract available
    
    
    July 2024
32. SEGAL NH, Tie J, Kopetz S, Ducreux M, et al
    COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer.
    Br J Cancer. 2024 Jul 25. doi: 10.1038/s41416-024-02796.
    PubMed     Abstract available
    
    
    
33. LAWLER T, Hibler E, Walts ZL, Giurini L, et al
    Associations of diabetes and mortality among colorectal cancer patients from the Southern Community Cohort Study.
    Br J Cancer. 2024 Jul 19. doi: 10.1038/s41416-024-02787.
    PubMed     Abstract available
    
    
    
34. HOU P, Shi P, Jiang T, Yin H, et al
    Correction: DKC1 enhances angiogenesis by promoting HIF-1alpha transcription and facilitates metastasis in colorectal cancer.
    Br J Cancer. 2024 Jul 17. doi: 10.1038/s41416-024-02801.
    PubMed    
    
    
    
35. MASUI H, Kawada K, Itatani Y, Hirai H, et al
    Synergistic antitumor activity by dual blockade of CCR1 and CXCR2 expressed on myeloid cells within the tumor microenvironment.
    Br J Cancer. 2024;131:63-76.
    PubMed     Abstract available
    
    
    
36. TSUKADA Y, Bando H, Inamori K, Wakabayashi M, et al
    Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
    Br J Cancer. 2024;131:283-289.
    PubMed     Abstract available
    
    
    June 2024
37. YANG L, Yi J, He W, Kong P, et al
    Correction: Death receptors 4/5 mediate tumour sensitivity to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer.
    Br J Cancer. 2024 Jun 26. doi: 10.1038/s41416-024-02768.
    PubMed    
    
    
    
38. EXARCHAKOU A, Rachet B, Lyratzopoulos G, Maringe C, et al
    What can hospital emergency admissions prior to cancer diagnosis tell us about socio-economic inequalities in cancer diagnosis? Evidence from population-based data in England.
    Br J Cancer. 2024;130:1960-1968.
    PubMed     Abstract available
    
    
    May 2024
39. YANG L, Yi J, He W, Kong P, et al
    Death receptors 4/5 mediate tumour sensitivitNot applicably to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer.
    Br J Cancer. 2024 May 25. doi: 10.1038/s41416-024-02673.
    PubMed     Abstract available
    
    
    
40. ZWART K, van Nassau SCMW, van der Baan FH, Koopman M, et al
    Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab.
    Br J Cancer. 2024 May 20. doi: 10.1038/s41416-024-02711.
    PubMed     Abstract available
    
    
    
41. VILLAREAL LB, Falcon DM, Xie L, Xue X, et al
    Hypoxia-inducible factor 3alpha1 increases epithelial-to-mesenchymal transition and iron uptake to drive colorectal cancer liver metastasis.
    Br J Cancer. 2024 May 1. doi: 10.1038/s41416-024-02699.
    PubMed     Abstract available
    
    
    
42. QIAO L, Liu Y, Yang Q
    Comment on: "Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial".
    Br J Cancer. 2024;130:1432-1433.
    PubMed    
    
    
    
43. CAI J, Lin K, Luo T, Weng J, et al
    Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial.
    Br J Cancer. 2024;130:1434-1440.
    PubMed     Abstract available
    
    
    
44. MENG XN, Ma JF, Liu YH, Li SQ, et al
    Dynamic genomic changes in methotrexate-resistant human cancer cell lines beyond DHFR amplification suggest potential new targets for preventing drug resistance.
    Br J Cancer. 2024;130:1819-1827.
    PubMed     Abstract available
    
    
    
45. KISAKOL B, Matveeva A, Salvucci M, Kel A, et al
    Identification of unique rectal cancer-specific subtypes.
    Br J Cancer. 2024;130:1809-1818.
    PubMed     Abstract available
    
    
    April 2024
46. REE AH, Saltyte Benth J, Hamre HM, Kersten C, et al
    First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial.
    Br J Cancer. 2024 Apr 25. doi: 10.1038/s41416-024-02696.
    PubMed     Abstract available
    
    
    
47. RIO-VILARINO A, Cenigaonandia-Campillo A, Garcia-Bautista A, Mateos-Gomez PA, et al
    Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
    Br J Cancer. 2024 Apr 4. doi: 10.1038/s41416-024-02667.
    PubMed    
    
    
    
48. BARANYI M, Molnar E, Hegedus L, Gabriel Z, et al
    Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
    Br J Cancer. 2024;130:1059-1072.
    PubMed     Abstract available
    
    
    
49. TIAN Y, Lin Y, Qu C, Arndt V, et al
    Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk.
    Br J Cancer. 2024 Apr 1. doi: 10.1038/s41416-024-02638.
    PubMed     Abstract available
    
    
    March 2024
50. FELIU J, Gamez-Pozo A, Martinez-Perez D, Perez-Wert P, et al
    Functional proteomics of colon cancer Consensus Molecular Subtypes.
    Br J Cancer. 2024 Mar 14. doi: 10.1038/s41416-024-02650.
    PubMed     Abstract available
    
    
    
51. ZHANG X, He Y, Li X, Shraim R, et al
    Circulating 25-hydroxyvitamin D and survival outcomes of colorectal cancer: evidence from population-based prospective cohorts and Mendelian randomisation.
    Br J Cancer. 2024 Mar 13. doi: 10.1038/s41416-024-02643.
    PubMed     Abstract available
    
    
    
52. RIO-VILARINO A, Cenigaonandia-Campillo A, Garcia-Bautista A, Mateos-Gomez PA, et al
    Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
    Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02649.
    PubMed     Abstract available
    
    
    
53. DENG LQ, Shi CJ, Zhou ST, Zeng WQ, et al
    EIF4A3-negatively driven circular RNA beta-catenin (circbeta-catenin) promotes colorectal cancer progression via miR-197-3p/CTNND1 regulatory axis.
    Br J Cancer. 2024 Mar 8. doi: 10.1038/s41416-024-02612.
    PubMed     Abstract available
    
    
    
54. GOURIOU C, Lemanski C, Pommier P, Le Malicot K, et al
    Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE.
    Br J Cancer. 2024;130:769-776.
    PubMed     Abstract available
    
    
    February 2024
55. KARAPETIS CS, Liu H, Sorich MJ, Pederson LD, et al
    Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials fro
    Br J Cancer. 2024 Feb 24. doi: 10.1038/s41416-024-02604.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.